We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sdi Group Plc | LSE:SDI | London | Ordinary Share | GB00B3FBWW43 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
2.50 | 3.62% | 71.50 | 71.00 | 72.00 | 74.00 | 69.50 | 69.50 | 1,046,525 | 15:22:26 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 67.58M | 3.87M | 0.0372 | 19.22 | 74.4M |
Date | Subject | Author | Discuss |
---|---|---|---|
06/9/2013 16:26 | Looks like share magazine has already generated some interest here. | nick2008 | |
06/9/2013 13:24 | The thing that may hold this back sadly is that it can be quite hard to trade online. | xlairways | |
06/9/2013 09:12 | Yeap! Saw the article in the shares magazine. Till date no one knows this stock outside of Advfn - so tip in shares magazine is a welcome news. | nick2008 | |
05/9/2013 14:45 | Tipped in the shares magazine today. Should give this some interest over the weekend :-) | xlairways | |
29/8/2013 08:30 | AGM notice RNS - change in the venue. | nick2008 | |
12/8/2013 00:06 | Cheers Woody - I'll take a look at CRX in the morning. | masurenguy | |
09/8/2013 18:23 | Mas nice to have you here too, i've had a nibble but like you will pyramid (as is my normal investment style) on news and eps growth.I'll assume the CEO reasons for limited holding are genuine. No advice intended but have a look at CRX it's a little ahead of SDI in it's development imv. I've a larger holding in CRX than SDI at present but i see both as very good potential for growth. WC | woodcutter | |
09/8/2013 16:57 | Thanks Nick - I've responded to your message. | masurenguy | |
09/8/2013 13:44 | MasurenguyCheck your PM message. Nick. | nick2008 | |
09/8/2013 13:39 | Woodcutter , MasurenguyWelcome guys - good to have you both on this thread. Masurenguy - I spoke to CEO earlier this year regarding his buying of stock and he gave a genuine reply which I can't post here. I'll private message it across to you. This is really the beginning - the new ProReveal will become the standard across 250 hospitals in the UK. Just imagine the potential across the world. DYORNick. | nick2008 | |
09/8/2013 12:52 | Interesting company. Joined AIM in Dec 2008 raising £2m @an IPO price of 12.5p. Since then they have issued 1.3m shares in acquiring Artemis and undertaken a placing of a further 4.8m shares in June @15p. This was to raise a further £850K in order to retire a convertible loan of £380k and to acquire more working capital. Current market cap is £4.3m based upon 24.2m shares in issue. Their eps is around 1p and they had a positive net cash balance of just under £400K at their April year end. Chairman Ford recently bought 100,000 shares @16.5p but I'd like to see the CEO buy a bigger stake since a total holding of 7,500 shares is hardly inspiring. The business is nicely geographically segmented with circa 30% in the US, 30% in Europe (ex-UK), 25% in Asia and 10% in the UK although that should increase further following the recent adoption of ProReveal at Eastwood Park. On to my Watchlist at this point as it looks as though it may be on the cusp of some accelerated growth. | masurenguy | |
06/8/2013 11:50 | Had a little nibble here today. Prospects look very interesting and if the forecast are to be believed and achieved then it looks very undervalued particularly with market leading position on some of it's products. If ProReveal sells at anything like it's potential it should multibag from here. And there does seem to be a good global distribution set up too. Although cash flow from operations was decent there's not a lot of cash on the balance sheet even allowing for the placing and loan repayment so managing the working capital requirements is going to be very important. The only down side i can see is the spread and illiquidity but that may well work in our favour if the mm's become short of stock. We may see a further placing possibly dependant on cash flows and WC requirements. One to put away for the longer term perhaps and maybe build as time goes on. Woody | woodcutter | |
26/7/2013 10:59 | Their main product which will sell like hot cakes is ProReveal. See this article from Journal of Hospital published earlier this year This confirms that Ninhydrin kits, currently used in hospitals are ineffective at detecting residual proteins. The way forward is SDI ProReveal which has got the first mover advantage. | nick2008 | |
26/7/2013 08:05 | Good morning all | nick2008 | |
25/7/2013 17:25 | Strange !! There is a buy at 21p - single buy trade yet the price drops down. | nick2008 | |
25/7/2013 14:59 | Extracts from Results - We believe that the recent SFDA order independently validates our technology as the "gold standard" and consider that our growth in Asia will continue to be fuelled by their need for excellent automation in the life sciences. - ProReveal is the only technology currently available that can meet nanogram levels of detection and could potentially be installed in 300 SSD's, in hospitals and private decontamination companies throughout the UK. - In 2013, 10 ProReveal systems were sold in the UK and Synoptics Health's UK distributor has installed three ProReveal systems in two major SSD's of leading London hospitals and one in an NHS training facility. - Synoptics Health is currently enjoying a first mover advantage in this untapped healthcare market sector not just in the UK but internationally. - During the period, the Synoptics Health Division appointed a network of six new distributors throughout the Asia-Pacific region - In Europe, the Division has appointed a new distributor in Germany and sold four systems, which are being independently evaluated by German hospitals. There are plans to have Dutch and Italian distributors in place, as well as a North American distributor within the next few months ensuring growth in demand for the ProReveal viewer and more importantly, a recurring revenue stream for the ProReveal spray over the coming year. | nick2008 | |
25/7/2013 14:53 | Wow! now Mike Creedon, Chief Executive Officer of the Company buys the stock... Note that Mike was the NEW CEO last year who has been turning around this company. | nick2008 | |
24/7/2013 20:03 | This is tightly held stock, so doesn't take much buying to push the price up. We'll see more buying this week. DYORNick. | nick2008 | |
24/7/2013 11:08 | 25k buy @20p went through.... | nick2008 | |
24/7/2013 10:43 | Another director buy at 16.5p. RNS out now. | nick2008 | |
24/7/2013 10:14 | Plus a very encouraging results RNS. | gnnmartin | |
24/7/2013 08:14 | RNS out - SDI is pleased to announce that the major international healthcare training centre, Eastwood Park, UK will be using ProReveal, a test to detect proteins on surgical instruments, to supplement the training of validation professionals on how to assess the efficacy of the decontamination processes. | nick2008 | |
12/7/2013 23:02 | Good buying today. | nick2008 | |
28/6/2013 15:57 | Strange to fall today? | nick2008 | |
28/6/2013 14:58 | hastings, thanks. I looked in today to see what's hit the shares. No news yet though. Very odd. Nigel Martin | gnnmartin |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions